Kopran Limited
Kopran Ltd. is an integrated Pharmaceutical Company, committed to manufacture and supply International Quality Formulations and Active Pharmaceutical Ingredients worldwide.
What Kopran files
- Others45
- Board Meeting9
- PPTs6
- JV/Acquisition6
- Investor Meet6
- Important5
Kopran's Q1 FY26-27 revenue climbed 13.88% YoY to **153.99 Cr** (from 135.22 Cr). EBITDA also rose 11.13% YoY, hitting **15.88 Cr**. However, Net Profit dipped 10.19% YoY to **6.70 Cr**, with EPS at Rs. 1.39. The API segment was the largest contributor with **95.38 Cr** revenue, while Formulations generated **57.09...
Kopran's Q3 FY26 results show strong revenue growth, up ~17% YoY to ₹194.28 Cr. Net profit for the quarter rebounded to ₹9.34 Cr, reversing Q2's loss, though slightly lower than last year's Q3. The API segment, a major growth driver, saw ~93% of its Q3 revenue from exports, led by...
Kopran Limited reported HY 2025-26 revenue of Rs 253.13 Cr, with a net loss of Rs 2.47 Cr. EBITDA stood at Rs 17.09 Cr, reflecting a 6.75% margin, and EPS was -Rs 0.51. The API segment, contributing Rs 158.70 Cr, saw strong sales in Carbapenem, Intermediate, and Macrolide products, with...
Kopran reported a challenging first half of FY26. Revenue from operations for Q2 stood at ₹117.91 Cr, a decline from ₹151.56 Cr YoY, leading to a net loss of ₹9.92 Cr for the quarter. For the half-year ending September 30, 2025, the company posted a net loss of ₹2.47 Cr,...
1. Financial Highlights: Kopran reported revenue of Rs. 623.59 Cr in FY25, nearly stable compared to Rs. 629.20 Cr in FY24. EBITDA slightly declined to Rs. 72.90 Cr with margins at 11.58%. Net profit dropped to Rs. 38.55 Cr from Rs. 50.96 Cr due to higher finance costs (Rs. 9.34...